Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients.

Microbial drug resistance (Larchmont, N.Y.) - 1 Sept 2024

Zou Peng, Chen Zhiquan, Tu Jijun, Chen Xinfeng, Liu Xuejian

Abstract excerpt

The majority of Klebsiella pneumonia isolates possess the extended-spectrum beta-lactamase (ESBL) enzymes. Therefore, K. pneumoniae can easily develop drug resistance. How to effectively overcome the problem of drug resistance in K. pneumoniae is still a research hotspot. This study aimed to compare the mutant prevention concentration (MPC) of ESBL-positive and ESBL-negative K. pneumoniae isolated from orthopedic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Lactamases
Share to Ciprofloxacin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Drug Resistance, Multiple, Bacterial

Share to Fluoroquinolones

Share to Klebsiella Infections

Share to Klebsiella pneumoniae

Share to Levofloxacin

Source

Identifiers

PMID: 39019029
DOI: 10.1089/mdr.2024.0023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients.PMID 39019029Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.Semantic proximity Read ↗

The new perspective of old antibiotic: In vitro antibacterial activity of TMP-SMZ against Klebsiella pneumoniaeSemantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.Semantic proximity Read ↗

Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis.Semantic proximity Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.